Current Research Interests
Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s esophagus (BE). His active studies investigate the role of inherited genetics in the etiology and biology of BE/EAC using a combination of statistical, computational, and experimental approaches. These include targeted and genome-wide discovery scans to identify novel genetic susceptibility loci; multi-omics informatics pipelines to prioritize single nucleotide variants based on estimated regulatory potential; and laboratory-based functional assays to validate and characterize candidate functional/causal variants, gene targets, and disease pathways. A second area of interest is the identification of novel molecular signatures of esophageal and ovarian cancers using high-throughput omics profiling technologies. The long-term translational goal of Dr. Buas’ research is to advance new strategies for prevention, risk assessment, and early detection. His work is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI).
View a full listing of Matthew F. Buas’ journal articles.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Matthew F. Buas discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures